Potency assay (off target):
The compound was selective over related enzymes like ENPP1,
phosphodiesterase 4 (PDE4) and PDE5 (enzymes with phosphodiesterase activity), and phospholipase A (PLA) or phospholipase C (PLC) (enzymes with phospholipase A or C activity, respectively). Moreover, GLPG1690 showed no inhibition in a panel of kinases. In a Cerep diversity panel (98 targets including receptors and ion channels), only 3 targets displayed more than 50% inhibition at 10 µM. (published on: Clinical Study Protocol GLPG1690-CL-202)